Sign In
Buy CELC
$88.95
-2.47 (-2.70%)
At Close: Jun 03, 2026
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
04:01pm, Wednesday, 15'th May 2024
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial re
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
07:05am, Wednesday, 08'th May 2024
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
07:05am, Thursday, 04'th Apr 2024
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian
Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript
06:40pm, Wednesday, 27'th Mar 2024
Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 27'th Mar 2024
MINNEAPOLIS, March 27, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial
Why Celcuity (CELC) Might Surprise This Earnings Season
12:21pm, Thursday, 21'st Mar 2024
Celcuity (CELC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
07:05am, Wednesday, 20'th Mar 2024
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wi
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
07:05am, Wednesday, 06'th Mar 2024
MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its partic
Celcuity to Participate in Cowen's 44th Annual Health Care Conference
07:05am, Wednesday, 28'th Feb 2024
MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its partici
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
07:05am, Tuesday, 20'th Feb 2024
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appoint
MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from p
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
11:02am, Friday, 01'st Dec 2023
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abs
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
08:05am, Wednesday, 22'nd Nov 2023
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its partici
Celcuity Inc. (CELC) Q3 2023 Earnings Call Transcript
12:41pm, Monday, 13'th Nov 2023
Celcuity Inc. (CELC) Q3 2023 Earnings Call Transcript
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
07:05am, Monday, 13'th Nov 2023
MINNEAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today reported financial re
